Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months
Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint
Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses
Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial
Cediranib Demonstates Control In Alveolar Soft Part Sarcoma
Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage
Shared Decisionmaking Called For In PSA Screening For Ages 55-69
ACCP Publishes Guidelines Recommending Low-Dose CT
Study: Routine CT Not Needed In Detecting DLBCL Remissions
Surveillance Following Surgery Sufficient in Stage I Seminoma
Fitness Reduces Risk of Death From Lung, Colorectal, Prostate Cancer in Middle-Aged Men
NCI CTEP Approved Trials For the Month of May
FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - NCI releases names of members of ad hoc working group—filling the void left by BSA
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - ACOG says it will no longer accept federal funding
- Bhattacharya: New grant review criterion is “not political”
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
